A PDF file should load here. If you do not see its contents
the file may be temporarily unavailable at the journal website
or you do not have a PDF plug-in installed and enabled in your browser.
Alternatively, you can download the file locally and open with any standalone PDF reader:
https://link.springer.com/content/pdf/10.1186%2Fs41181-016-0006-4.pdf
Editorial - EJNMMI radiopharmacy and chemistry
Elsinga EJNMMI Radiopharmacy and Chemistry
Editorial - EJNMMI radiopharmacy and chemistry
Philip H. Elsinga
-
EJNMMI Radiopharmacy and Chemistry is a new journal within the EJNMMI family
and is now ready to launch the first articles on-line. The aim of EJNMMI
Radiopharmacy and Chemistry is to publish research in the field of new imaging and
radionuclide based therapeutic agents that can be applied in nuclear medicine and
molecular imaging.
This new journal provides an ideal platform for chemists, pharmacists and basic
scientists to promote science, but also to exchange opinions and to provide updates on
developments that have effect on availability of imaging agents for the clinic such as
regulatory aspects.
EJNMMI Radiopharmacy and Chemistry reports original research articles, review
papers, guidelines on application of imaging or radionuclide therapy agents, editorials,
and letters to the editor. Research articles on novel radiochemistry, new
radiopharmaceuticals including their first biological evaluation, molecular imaging agents including
optical imaging, MRI, and hybrid probes, are the main focus of the journal. To
translate imaging and radionuclide therapy agents to the clinic, legislative issues related to
their production and safety can be presented as well in from of guidelines or position
papers.
Radiopharmacy and radiochemistry are very essential for the development of nuclear
medicine and molecular imaging and for its position in personalized medicine.
In this way, EJNMMI Radiopharmacy and Chemistry is very complementary to the
other journals of the EJNMMI family, which focus mainly on (pre)clinical, technical
and physical perspectives of nuclear medicine. With this new Journal we hope to
establish a unique platform for our community.
Since the launch of EJNMMI Radiopharmacy and Chemistry in late October 2015
several manuscripts have been submitted, of which the first have now gone through
the whole review process. So, we can now present the first number of accepted
manuscripts. The Journal starts with a position paper developed by the EANM
Radiopharmacy Committee on toxicity of radiopharmaceuticals, some new developments related
to 68Ga-radiochemistry and an early preclinical studies. In addition some invited
articles and original research articles are in the pipeline.
We are happy that a respectable number of scientist from all over the world have
accepted the invitation to participate in the Editorial Board of EJNMMI Radiopharmacy
and Chemistry. Their expertise covers a wide range of expertise in PET, SPECT and
Molecular Imaging Radiopharmacy and Chemistry. (...truncated)